modified vaccinia virus Ankara

modified vaccinia virus Ankara

,

MVA

An attenuated form of vaccinia virus that does not replicate itself efficiently. It has been used as an antigen carrier and as an adjuvant in the development of vaccines against both infectious illnesses and cancers.
Mentioned in ?
References in periodicals archive ?
Modified vaccinia virus Ankara (MVA) is a promising viral vector platform for the development of influenza vaccines (5).
Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.
The PEACHI Consortium members have employed replication-defective simian adenovirus (ChAd) and modified vaccinia virus Ankara (MVA) vector technology to develop the most immunogenic HCV and HIV-1 vaccines to date.
9 million for the development of recombinant Modified Vaccinia virus Ankara (MVA)-based vaccines, building on the company's MVA-BN[sup.
Called Imvamune, the vaccine is derived from the parent strain Modified Vaccinia virus Ankara (MVA-BN), a highly attenuated pox virus that has lost the capacity to replicate in human cells, according to its maker, Bavarian Nordic A/S, a Denmark-based biotechnology company.
The European Patent is directed to Modified vaccinia virus Ankara (MVA) which abortively infects neonates used for inducing or enhancing the maturation of the immune system, and thus, for example, concerns the high risk group of the young with an immature immune system.
A less virulent stock consisting of modified vaccinia virus Ankara (MVA) stock has shown improved safety in clinical trials.
IMVAMUNE (MVA-BN) is a non-replicating smallpox vaccine derived from the modified vaccinia virus Ankara.
Acquires Vivacs GmbH Along with Rights to Modified Vaccinia Virus Ankara (MVA) Strain and Monoclonal Vector Technology Platform (MVAtor(TM))
As a result of the transaction, Emergent BioSolutions will acquire a worldwide license to a modified vaccinia virus Ankara (MVA) strain that is owned by the Bavarian State Ministry of the Environment, Public Health and Consumer Protection (StMUGV).
29) have shown that intranasal or intramuscular inoculations of mice with highly attenuated modified vaccinia virus Ankara (MVA) vaccines encoding full-length SARS-CoV S protein also produce neutralizing antibodies with mean neutralizing titers of 1:284.
Subsequently, this initial response is then "boosted" using a Modified Vaccinia virus Ankara (MVA) based vector, which codes for the same hepatitis B specific antigens as the DNA prime.

Full browser ?